Researchers at Ohio University report that mice engineered to produce a growth hormone receptor antagonist, the same molecule class that became the acromegaly drug Pegvisomant, live significantly longer than normal littermates. In a formal survival study of 351 C57BL/6J mice, median lifespan rose 23.0 percent in females and 2.9 percent in males, with maximal lifespan up 29.1 percent and 12.2 percent respectively. A separate cohort of two-year-old animals showed better grip strength and lower frailty scores in the antagonist mice despite carrying substantially more body fat. The result overturns the same laboratory’s own 2003 finding, which had reported no lifespan benefit in this mouse line. The headline caveat is that the control animals, particularly the females, were unusually short-lived by modern reference standards, which inflates the apparent size of the benefit.
For three decades the growth hormone story in aging research has run almost entirely on genetics. Mice that cannot make growth hormone, or whose cells cannot hear it, outlive normal mice by margins no drug has matched. The longest-lived laboratory mouse on record, a dwarf named Yoda, reached nearly five years. Every one of those animals was built by removing a gene before birth. That is a useful proof of principle and a useless prescription, because nobody is going to delete a receptor gene from a human adult.
The open question has been whether the same benefit survives the translation from genetics to pharmacology. Growth hormone action can be blocked with a protein antagonist. One such antagonist, Pegvisomant, has been approved and in clinical use for acromegaly for over two decades, with a safety record built on real patients. It has never been tested for lifespan because it binds rodent receptors too weakly to work in mice.
A team led by Edward List and John Kopchick at Ohio University, the laboratory where the antagonist chemistry was originally discovered, found a way around that. Instead of dosing mice with the human drug, they used a transgenic line created in 1991 that manufactures its own bovine growth hormone antagonist continuously. These mice have been maintained in the same colony for more than twenty generations.
The survival data are unambiguous in direction. Across both sexes pooled, the antagonist mice had a hazard ratio of 0.57, meaning that at any given moment they were about 43 percent less likely to die than controls. Female mice drove most of that effect, with a mean lifespan increase of 186 days. Males gained 57 days on average, and only 23 days at the median, an effect that barely cleared statistical significance.
There is a wrinkle that makes this story more interesting than a straightforward confirmation. In 2003 this same laboratory looked at this same mouse line and found nothing. The authors now argue the earlier attempt was underpowered, mixed breeders with non-breeders, and used the wrong statistical test. That explanation is reasonable, but a reversal within one colony is the kind of thing that deserves independent replication before it hardens into consensus.
The second finding is arguably the more provocative one. At two years of age the antagonist mice were fatter, shorter and leaner in muscle mass, yet scored better on a standardised frailty index and gripped harder per gram of lean tissue. This is the paradox that keeps recurring in growth hormone biology. These animals look metabolically unhealthy by every crude measure and behave metabolically healthy by every functional one, with fat preferentially deposited under the skin rather than around the organs.
What the paper does not do is test the drug. It tests a lifelong genetic surrogate for the drug, starting from conception, producing dwarf animals. Whether an adult given a receptor antagonist at a clinical dose gets any of this remains unknown, and the authors are careful to say so.
Actionable Insights
The immediate practical message is negative rather than positive. Nothing here supports taking growth hormone antagonists (blockers). Pegvisomant is a daily injection for a rare pituitary tumour condition, it requires liver monitoring, and no human longevity data exist.
The useful takeaway is directional. If you are using growth hormone, growth hormone secretagogues such as ipamorelin or CJC-1295, or anything else marketed to raise IGF-1 for anti-aging purposes, this paper adds to a very large body of animal evidence pointing the opposite way. Lower growth hormone signalling, not higher, is what lengthens mammalian lifespan in every model tested.
How large is the benefit? In females the effect size was Cohen’s d of roughly 0.79, which is conventionally called large. In plain terms, the average treated female outlived about 79 percent of untreated females. In males d was roughly 0.28, a small effect, where the average treated male outlived about 61 percent of controls. The hazard reduction was 55 percent in females and 28 percent in males.
Two secondary lessons. First, body fat percentage on its own is a poor health marker. These mice were substantially fatter and measurably less frail, because the fat went subcutaneous rather than visceral. Second, absolute lean mass fell sharply while strength per gram of muscle rose. Anything that lowers growth hormone signalling likely needs resistance training as a counterweight.
Context and Source
- Open Access Paper: Growth Hormone Receptor Antagonism Extends Lifespan
- Institution: Institute of Molecular Medicine and Aging, and Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio
- Country: United States
- Journal: Aging Cell (Wiley, on behalf of the Anatomical Society)
- Journal impact evaluation: The impact score of this journal is 7.7 (2025 Journal Impact Factor; CiteScore 13.8), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.